From: Recurrent colorectal liver metastasis patients could benefit from repeat hepatic resection
Variable | Local treatment | Systemic chemotherapy | P value | |
---|---|---|---|---|
Resection | RFA | |||
Patients demographics | n = 88 | n = 85 | n = 127 | |
Age (years) | 55.6 ± 10.3 | 57.7 ± 9.3 | 56.1 ± 9.8 | 0.75 |
Sex ration (M:F) | 57:31 | 59:26 | 80:47 | 0.83 |
Primary T | ||||
T1-2 | 7 (8.0%) | 7 (8.2%) | 18 (14.2%) | 0.23 |
T3-4 | 81 (92.0%) | 78 (91.8%) | 109 (85.8%) | |
Primary N | ||||
N0 | 54 (61.4%) | 66 (77.6%) | 94 (74.0%) | 0.82 |
N1-2 | 34 (38.6%) | 19 (22.4%) | 33 (26.0%) | |
Primary tumor location | ||||
Colon | 55 (62.5%) | 52 (61.2%) | 78 (31.4%) | 0.95 |
Rectum | 33 (37.5%) | 33 (38.8%) | 49 (38.6%) | |
Right side | 24 (27.3%) | 17 (20.0%) | 34 (26.8%) | 0.75 |
Left side | 64 (72.7%) | 68 (80.0%) | 93 (73.2%) | |
Timing of liver metastasis | ||||
Synchronous | 72 (81.8%) | 78 (91.8%) | 110 (86.6%) | 0.53 |
Metachronous | 16 (18.2%) | 7 (8.2%) | 17 (13.4%) | |
Metastasis no | 1 (1–7) | 1 (1–3) | 2 (1–5) | 0.00 |
Metastasis size(mm) | 23.1 ± 15.8 | 15.6 ± 1.7 | 19.6 ± 10.2 | 0.00 |
Localization of liver metastases | ||||
Unilobar | 63 (71.6%) | 70 (82.4%) | 72 (56.7%) | 0.00 |
Bilobar | 25 (28.4%) | 15 (17.6%) | 55 (43.3%) | |
CEA > 50 | 13 (14.8%) | 4 (4.7%) | 5 (3.9%) | 0.00 |
CA199 > 100 | 10 (11.4%) | 6 (7.1%) | 8 (6.3%) | 0.18 |
Ras status | ||||
Wild | 62 (70.5%) | 50 (58.8%) | 77 (60.6%) | 0.49 |
Mutation | 26 (29.5%) | 35 (41.2%) | 50 (39.4%) | |
Preoperative chemotherapy | 49 (55.7%) | 25 (29.4%) | 127 (100%) | NA |
Up-front local treatment | 39 (44.3%) | 60 (70.6%) | 0 | |
No. of lines | ||||
First line | 25 (28.4%) | 12 (14.1%) | 70 (55.1%) | NA |
Second line | 24 (27.3%) | 13 (15.3%) | 47 (37.0%) | |
Others | 0 | 0 | 10 (7.9%) | |
Regimen | ||||
Oxaliplatin | 18 (20.5%) | 9 (10.6%) | 49 (38.6%) | NA |
Irinotecan | 31 (35.2%) | 16 (18.8%) | 70 (55.1%) | |
Others | 0 | 0 | 8 (6.3%) | |
Biological agents | 39 (44.3%) | 20 (23.5%) | 95 (74.8%) | NA |
Bevacizumab | 29 (33.0%) | 18 (21.2%) | 70 (55.1%) | |
Cetuximab | 10 (11.3%) | 2 (2.3%) | 25 (19.7%) | |
Response to chemotherapy | ||||
Complete | 0 | 0 | 0 | NA |
Partial | 4 (4.5%) | 2 (2.4%) | 21 (16.5%) | |
Stable disease | 45 (51.1%) | 23 (27.1%) | 89 (70.1%) | |
Progressive disease | 0 | 0 | 17 (13.4%) | |
Intraoperative RFA | 8 (9.1%) | NA | NA | |
Operation time | 204.4 ± 89.0 | NA | NA | NA |
Blood lose | 274.1 ± 77.1 | NA | NA | NA |
RBC transfusion | 2 | NA | NA | NA |
R1 resection | 6 | NA | NA | NA |
Complication | 4 | NA | NA | NA |
Major | 1 | 0 | NA | NA |
Adjuvant chemotherapy | 66 (75%) | 62 (73.0%) | NA | NA |